Oncogene - Table of Contents alert Volume 37 Issue 4

If you are unable to see the message below, click here to view.

Advertisement Are you new to ChIP? Diagenode can help.  Diagenode provides complete ChIP-qPCR and ChIP-seq solutions making epigenetics research accessible. Eliminate the challenges of your epigenetics workflow with validated antibodies, kits, Bioruptor chromatin shearing systems, and our unique ChIPmentation and ChIP-seq automation system. Check out our new website that take you through a step-by-step guide of what you need for ChIP.  Learn more   TABLE OF CONTENTS Volume 37, Issue 4 (January 2018) In this issue Original Articles Short Communication Also new AOP   Advertisement   GEP-NET: COMPETE phase III clinical trial is open for recruitment COMPETE evaluates the efficacy and safety of Targeted Radionuclide Therapy with n.c.a. 177Lu-Edotreotide (Solucin®) in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET). For further information about inclusion, exclusion criteria and more, please visit our website.  Sign up for e-alerts Recommend to your library Web feed Subscribe Original Articles A regulatory circuit HP1γ/miR-451a/c-Myc promotes prostate cancer progression C Chang, J Liu, W He, M Qu, X Huang et al. Oncogene 2017 37 :415 - 426; October 02, 2017; 10.1038/onc.2017.332   Abstract | Full Text AKT overactivation can suppress DNA repair via p70S6 kinase-dependent downregulation of MRE11 D Piscitello, D Varshney, S Lilla, M G Vizioli, C Reid et al. Oncogene 2017 37 :427 - 438; October 02, 2017; 10.1038/onc.2017.340   Abstract | Full Text Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy V Mett, E A Komarova, K Greene, I Bespalov, C Brackett et al. Oncogene 2017 37 :439 - 449; October 02, 2017; 10.1038/onc.2017.346   Abstract | Full Text The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia J Serio, J Ropa, W Chen, M Mysliwski, N Saha et al. Oncogene 2017 37 :450 - 460; September 25, 2017; 10.1038/onc.2017.337   Abstract | Full Text EZH2 promotes neoplastic transformation through VAV interaction-dependent extranuclear mechanisms N Venkatesan, J F Wong, K P Tan, H H Chung, Y H Yau et al. Oncogene 2017 37 :461 - 477; October 02, 2017; 10.1038/onc.2017.309   Abstract | Full Text TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1–TSC2 complex P Guo, X Ma, W Zhao, W Huai, T Li et al. Oncogene 2017 37 :478 - 488; October 02, 2017; 10.1038/onc.2017.349   Abstract | Full Text A growth hormone receptor SNP promotes lung cancer by impairment of SOCS2-mediated degradation Y Chhabra, H Y Wong, L F Nikolajsen, H Steinocher, A Papadopulos et al. Oncogene 2017 37 :489 - 501; October 02, 2017; 10.1038/onc.2017.352   Abstract | Full Text Aurora-A-mediated phosphorylation of LKB1 compromises LKB1/AMPK signaling axis to facilitate NSCLC growth and migration X Zheng, J Chi, J Zhi, H Zhang, D Yue et al. Oncogene 2017 37 :502 - 511; October 02, 2017; 10.1038/onc.2017.354   Abstract | Full Text Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition K A Gelato, L Schöckel, O Klingbeil, T Rückert, R Lesche et al. Oncogene 2017 37 :512 - 521; October 09, 2017; 10.1038/onc.2017.325   Abstract | Full Text Essential role of METTL3-mediated m6A modification in glioma stem-like cells maintenance and radioresistance A Visvanathan, V Patil, A Arora, A S Hegde, A Arivazhagan et al. Oncogene 2017 37 :522 - 533; October 09, 2017; 10.1038/onc.2017.351   Abstract | Full Text LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation Y He, Y Zhao, L Wang, L R Bohrer, Y Pan et al. Oncogene 2017 37 :534 - 543; October 09, 2017; 10.1038/onc.2017.353   Abstract | Full Text Short Communication Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo C Lambrecht, L Libbrecht, X Sagaert, P Pauwels, Y Hoorne et al. Oncogene 2017 37 :544 - 552; October 02, 2017; 10.1038/onc.2017.350   Abstract | Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.